<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="?"><plain>Why does it seem that, repeatedly, when a new treatment with a striking effect is discovered in the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> field, it is effective for a very rare <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> type </plain></SENT>
<SENT sid="1" pm="."><plain>For example, groundbreaking therapeutic discoveries have been made for extremely uncommon <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> such as hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, <z:mpath ids='MPATH_317'>seminoma</z:mpath>, <z:hpo ids='HP_0100723'>gastrointestinal stromal tumor</z:hpo>, (del)5q <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, progress in the most common and most intensively studied <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> - lung, breast, prostate, and <z:hpo ids='HP_0003003'>colon cancer</z:hpo> - has been slow and incremental </plain></SENT>
<SENT sid="3" pm="."><plain>We hypothesize that the reason for this phenomenon is that the pathophysiologic basis for a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> being rare is one and the same as the reason that it may ultimately be so treatable </plain></SENT>
<SENT sid="4" pm="."><plain>That is, if a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> can be derived only via a single aberrant molecular genetic aberration, then it should be both rare and easily targeted by a molecular <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapeutic approach </plain></SENT>
<SENT sid="5" pm="."><plain>If, on the other hand, many distinct pathways can lead to the development of a specific <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> type, it should occur much more commonly and be significantly more difficult to treat </plain></SENT>
<SENT sid="6" pm="."><plain>The corollary to our hypothesis is the prediction that new therapies will continue to show their most salutary effects in rare <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, only by stratifying the <z:e sem="disease" ids="C1333132" disease_type="Neoplastic Process" abbrv="">common tumors</z:e>, especially when using targeted agents, into the molecular subsets of diseases that compose them are we likely to achieve a substantial effect in these disorders </plain></SENT>
</text></document>